Medical Week Daily Pro
The week's most important medical story, explained in depth.
Each deep-dive takes one new drug approval, safety action, major trial readout or regulatory change and explains it in plain language: who it applies to, what the numbers really say, and what it means for patients, clinicians and industry. Every claim is cited to a primary source (FDA, EMA, CDSCO, NEJM, The Lancet, ClinicalTrials.gov).
A new deep-dive every week. The daily digest stays free.
Deep-dives
Regulatory change for health startups · 2026-10-27 · 7 min read
Wellness app or medical device? FDA's 2026 rules for wearables and clinical decision software, a founder's guideFDA reissued two digital health guidances in January 2026 that decide whether many health startups need FDA clearance at all. This guide covers what changed, the tests FDA applies, and the claims that move a product across the line.
Pro · 5 primary sources
Approval explained · 2026-10-27 · 6 min read
Hibsago (bepirovirsen): what FDA's first antisense drug for chronic hepatitis B does, who it is for, and what the numbers really sayOn 20 October 2026 FDA approved a 24-week add-on injection that let a minority of patients stop all hepatitis B medicine. Here is the approval, line by line.
Pro · 1 primary source
Trial readout breakdown · 2026-10-27 · 6 min read
Three phase 3 IgA nephropathy readouts in one week: atacicept, sibeprenlimab and povetacicept, explainedNEJM published results for three drugs that target the BAFF/APRIL pathway between 22 and 23 October 2026. What each trial measured, what it found, and why the endpoints matter.
Pro · 5 primary sources
What Pro is, and is not
- Plain-language analysis for curious readers, healthcare workers, pharma, PV and regulatory professionals, investors and health-tech founders.
- Primary sources only, with every claim linked. We never invent data.
- Not medical advice. Pro is informational and educational only. Consult a qualified professional about your own care.
- No sponsored content inside deep-dives.